Quality of life assessment in patients undergoing treatment for oesophageal carcinoma

British Journal of Surgery

Volumn 83, Issue 3, 1996, Pages 423-424

  Morgan, G ^a  

^a West Glamorgan Health Authority   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN E2; TUMOR MARKER;

DRUG EFFECT; ESOPHAGUS CARCINOMA; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030004637     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.1800830347     Document Type: Letter

References (5)

1. Morgan GP. Deleterious effects of prostaglandin E, in reflux oesophagitis. Medical Hypothesis (in press).
2. Morgan GP. NSAIDs and the chemoprevention of colorectal and oesophageal cancers. Gut (in press).
3. Morgan GP. Tumoricidal effect of indomethacin in the oesophagus. Postgrad Med J 1993; 69: 960 (Letter).
4. Morgan GP, Williams JG. Inflammatory mediators in the oesophagus. Gut 1994; 35: 297-8.
5. Zhou JH, Jiang YG. Pre- and postoperative NK cell number and plasma levels of TNF and PGE, in patients with oesophageal carcinoma and their clinical significance. Chinese Journal of Oncolosy 1994; 16: 132-6.